跳至主要内容
临床试验/NCT06654297
NCT06654297招募中1 期

The Safety and Feasibility of Neoadjuvant Camrelizumab With Palbociclib for the Treatment of Resectable Esophageal Squamous Cell Carcinoma:A Phase 1 Trial

West China Hospital1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2024年8月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
入组人数
6
试验地点
1
主要终点
Safety of combination camrelizumab and palbociclib as assessed by number of participants who experience adverse events

研究概览

简要总结

The purpose of this study is to explore the safety and feasibility of anti-programmed cell death 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Palbociclib, as a new neoadjuvant treatment regimen for patients with resectable esophageal squamous cell carcinoma (ESCC).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with esophageal squamous cell cancer by gastroscopic biopsies.
  • The primary tumor should be located in the thorax and evaluated resectable( cT1b-T3N1-3M0, cT3N0M0) by CT/MRI/EUS
  • The patients should be at the range of 18-75 years old, Eastern Cooperative Oncology Group (ECOG) 0-
  • The patients should have no functional disorders in major organs. Blood routine tests, as well as lung, liver, kidney, and heart functions should be basically normal.
  • The patients should be able to understand our research and be willing to accept surgical treatment and sign the informed consent.

排除标准

  • The stage of tumor is T4b (AJCC/International Union Against Cancer (UICC) 8th Edition) and cannot be resected.
  • Currently undergoing other chemotherapy, radiotherapy, targeted therapy or immunotherapy.
  • History of other malignancies.
  • Have an active autoimmune disease requiring systemic treatment or a documented history of clinically severe autoimmune disease.
  • Any history of allergic disease, or a sever hypersensitivity reaction to drugs, or allergy to the study drug components.
  • Presence of serious medical diseases, such as grade II and above cardiac dysfunction (NYHA criteria), ischemic heart diseases, etc.
  • The patients with severe systematic intercurrent diseases, including active infection or poorly controlled diabetes, coagulation disorders, hemorrhagic tendency, or those undergoing thrombolysis or anticoagulant therapy etc. are excluded from the study.
  • Female participants who test positive for a serum pregnancy test, are in the lactation period, or are at a childbearing stage and unwilling to use contraception measures during the research are excluded.
  • Received any investigational drug within 4 weeks prior to the first dose, or concurrently enrolled in another clinical trial.
  • Any other factors that are not suitable for inclusion in this study judged by investigators.

研究组 & 干预措施

Camrelizumab+Palbociclib(100mg) 3 patients

Experimental

For palbociclib, there is 2 dose levels, 100mg qd and 125 mg qd, and if no patients experience DLT on 100mg level, 125mg level will be administered.

干预措施: Camrelizumab (Drug)

Camrelizumab+Palbociclib(100mg) 3 patients

Experimental

For palbociclib, there is 2 dose levels, 100mg qd and 125 mg qd, and if no patients experience DLT on 100mg level, 125mg level will be administered.

干预措施: Palbociclib(100mg) (Drug)

Camrelizumab+Palbociclib(125mg) 3 patients

Experimental

For palbociclib, there is 2 dose levels, 100mg qd and 125 mg qd, and if no patients experience DLT on 100mg level, 125mg level will be administered.

干预措施: Camrelizumab (Drug)

Camrelizumab+Palbociclib(125mg) 3 patients

Experimental

For palbociclib, there is 2 dose levels, 100mg qd and 125 mg qd, and if no patients experience DLT on 100mg level, 125mg level will be administered.

干预措施: Palbociclib(125mg) (Drug)

结局指标

主要结局

Safety of combination camrelizumab and palbociclib as assessed by number of participants who experience adverse events

时间窗: up to 15 weeks

Number of participants who experience grade 1 or higher adverse events, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)

Feasibility of combination camrelizumab and palbociclib as assessed by number of participants who experience adverse events

时间窗: up to 15 weeks

Patients proceed to surgery without experiencing prolonged treatment-related delays. An extended treatment-related delay will be considered if it exceeds 37 days from the initially scheduled surgery date. In terms of feasibility, if there is any treatment toxicity of any grade that could adversely impact prognosis, as judged by the investigators, the planned operative date should be re-evaluated.

次要结局

  • Maximum Tolerated Dose (MTD) of palbociclib as determined by number of participants with dose limiting toxicities (DLT)(up to 15 weeks)
  • Major Pathologic Response(up to 15 weeks)
  • Objective response rate (ORR)(up to 15 weeks)
  • Progression free survival(PFS)(Up to 2 years)
  • Overall survival (OS)(Up to 2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Xingchen Peng

professor

Sichuan University

研究点 (1)

Loading locations...

相似试验

Neoadjuvant Camrelizumab With Palbociclib for... | 临床试验